Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Completed sale of KRESLADI-related Rare Pediatric Disease Priority Review Voucher on June 10, 2026.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Completed sale of KRESLADI-related Rare Pediatric Disease Priority Review Voucher on June 10, 2026
- Gross cash proceeds of $180.0 million received at closing
- Non-operating liquidity event potentially strengthening funding capacity for Rocket’s development pipeline
- Purchase agreement dated April 26, 2026, with full terms to be filed in the June 30, 2026 Form 10-Q
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD language only; no substantive investor information disclosed
- Exhibit materials, if any, excluded from automatic incorporation into Securities Act or Exchange Act filings
Item EX-99.1 · Exhibit EX-99.1
- Closed sale of KRESLADI Rare Pediatric Disease PRV for $180 million gross proceeds
- Pro forma cash, cash equivalents and investments increased from $144.4 million to approximately $322.6 million
- Non-dilutive proceeds extend expected operating runway into second quarter 2028
- Sale monetizes FDA approval-related asset, strengthening funding for cardiovascular and other gene-therapy programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.